Navigation Links
Heart failure protection through gene therapy

The causes of heart failure are many including genetic abnormalities. Earlier studies have shown that malfunctioning of a gene called phospholamban contributes to heart failure and this discovery is now being used as a basis for a gene therapy approach in protecting against heart failure.

The research which was carried out on hamsters born predisposed to heart failure showed that delivering a gene that helps the heart to contract protects// from heart failure. Researchers said that the animals' heart function improved when they were delivered a modified form of the gene phospholamban. They found that those animals who got the gene were protected against heart failure while those who did not get the gene were not protected.

Researchers hope they will be able to use a cardiac catheter to deliver the gene to humans, if further research on pigs, which is underway, proves to be successful.


'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
Other Medicine News:Health News:Cardiff scientists study acute infection in end-stage kidney disease patients 2Health News:Statement by the National Patient Advocate Foundation on President-Elect Obama's Victory 2Health News:Pharmaceutical Industry Needs to Speed Up Transformation to Meet Changing Market Dynamics, According to Ernst & Young Report 2Health News:Pharmaceutical Industry Needs to Speed Up Transformation to Meet Changing Market Dynamics, According to Ernst & Young Report 3Health News:Pharmaceutical Industry Needs to Speed Up Transformation to Meet Changing Market Dynamics, According to Ernst & Young Report 4Health News:Conrad J. Heilman to Succeed Joseph S. Tempio as President and CEO of Tunnell Consulting 2Health News:Conrad J. Heilman to Succeed Joseph S. Tempio as President and CEO of Tunnell Consulting 3Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 2Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 3Health News:GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director 2Health News:GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director 3
Breaking Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Zimmer Holdings to Present at BMO Capital Markets Ninth Annual Focus on Healthcare Conference 53086 1Less Common Procedures Less Common Than Thought 53082 1Less Common Procedures Less Common Than Thought 53082 2Carboxytherapy and Mesotherapy Unproven Warns The Physicians Coalition for Injectable Safety 53079 1Carboxytherapy and Mesotherapy Unproven Warns The Physicians Coalition for Injectable Safety 53079 2Carboxytherapy and Mesotherapy Unproven Warns The Physicians Coalition for Injectable Safety 53079 3